What does it look like to build a pharmacy that not only survives—but thrives?

In this episode of Independent Insights, host Britney Woods talks with Dave Randolph, owner of Dave’s Pharmacy, and Mikayla Smith, pharmacy manager, about their journey as an independent pharmacy serving rural communities. Together, these Health Mart Pharmacy of the Year award winners discuss expanding clinical services, supporting staff through growth, and finding sustainable ways to meet patient needs when access to care is limited.

Through candid stories and practical lessons, this episode highlights how thoughtful advocacy, innovation, and leadership can help strengthen both patient care and the longterm health of an independent pharmacy.

Host
Britney Woods, PharmD
Sr. Manager, Community Pharmacy
McKesson / Health Mart

Guests
Dave Randolph, RPh
Pharmacy Owner
Dave's Pharmacy

Mikayla Smith, CPhT
AA Business Pharmacy Manager
Dave's Pharmacy

References
Tune into these additional Independent Insights episodes for more details on ECAPs and hosting a legislator mentioned during this podcast episode:

• Episode 19: Your Pharmacy, Your Voice: Why HR3164 (ECAPS) Needs You
• Episode 17: From Aisles to Action: Welcoming Legislators into Your Pharmacy
  
  
  

The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

Artificial intelligence (AI) is rapidly transforming the healthcare landscape—and pharmacy is no exception. This course explores emerging and potential uses of AI in pharmacy practice, including workflow automation, drug information access, and tools that support patient care and clinical decision-making. You will gain insight into practical considerations, limitations, and ethical responsibilities pharmacists must navigate as AI becomes more integrated into practice.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Timothy Aungst, PharmD
Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Identify current and potential uses of AI that support pharmacist-led patient care services.
2. Describe considerations, limitations, and ethical concerns related to implementing AI tools in pharmacy practice.

Rachel Maynard and Timothy Aungst have no relevant financial relationships with ineligible companies to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-060-H04-P
Initial release date: 3/23/2026
Expiration date: 3/23/2027
Additional CPE details can be found here.

Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Sarah Grady, PharmD, BCPS, BCPP
Professor of Pharmacy Practice, Clinical Pharmacist
Drake University/Broadlawns Medical Center

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only.
To learn more about Health Mart, click here: https://join.healthmart.com/

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.
2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.

Rachel Maynard and Sarah Grady have no relevant financial relationships to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-059-H01-P
Initial release date: 3/16/2026
Expiration date: 3/16/2027

Additional CPE details can be found here.

GLP‑1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP‑1 for chronic weight management and ongoing investigations into GLP‑1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP‑1s and how pharmacists can anticipate and support their evolving role in patient care.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Christine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP
Professor, Pharmacy Practice and Clinical Pharmacist
Midwestern University

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize recent regulatory and clinical updates related to GLP‑1 receptor agonists, including new formulations.
2. Describe emerging areas of research into the use of GLP‑1 therapies beyond diabetes and obesity treatment.

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated.

0.1 CEU/1.0 Hr
UAN: 0107-0000-26-081-H01-P
Initial release date: 3/9/2026
Expiration date: 3/9/2027
Additional CPE details can be found here.

Recent changes to childhood vaccine recommendations have introduced shared clinical decision‑making for several immunizations that were previously universally recommended, creating confusion among patients and providers alike. This course explains what shared clinical decision‑making means in the context of immunizations, examines how it affects pediatric vaccine discussions, and highlights opportunities for pharmacists to support informed, individualized conversations with patients and caregivers. You will gain clarity on how to apply shared clinical decision‑making principles—alongside proven health coaching strategies—to strengthen patient trust and foster more meaningful dialogue in pharmacy practice.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Elizabeth Skoy, PharmD, RPh
Professor
North Dakota State University

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe shared clinical decision-making and how it applies to recent pediatric vaccine recommendations.
2. Identify the pharmacist's roles in counseling, education, and facilitating shared clinical decision-making conversations with patients and caregivers.

Rachel Maynard and Elizabeth Skoy have no relevant financial relationships with ineligible companies to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-077-H01-P
Initial release date: 3/2/2026
Expiration date: 3/2/2027
Additional CPE details can be found here.

A familiar format, a subtle shift, and something worth sticking around for. This episode includes an introduction to the next chapter of Independent Insights.

Host
Suzanne Feeney, PharmD
Sr. Director, Pharmacy Solutions
McKesson / Health Mart

Guests
Britney Woods, PharmD
Sr. Manager, Community Pharmacy
McKesson / Health Mart

The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

As gabapentin climbs the ranks to become one of the most prescribed medications in the U.S., questions about its safety and scope of use are also rising. This episode explores recent trends in gabapentin use, highlights key patient safety concerns, and examines pharmacist-led opportunities to reduce risks through education and medication review. You will walk away with timely insights to help navigate the growing complexities and responsibilities associated with gabapentin use.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Nakia Duncan, PharmD BCGP, BCPS
Associate Professor/ Pain& Palliative Care Clinical Pharmacist
Texas Tech Health Science Center - School of Pharmacy

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize recent national prescribing trends and safety concerns associated with gabapentin use.
2. Identify pharmacist-led strategies to support safe use, patient education, and medication review involving
gabapentin.

Rachel Maynard and Nakia Duncan have no relevant financial relationships with ineligible companies to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-053-H01-P
Initial release date: 2/23/2026
Expiration date: 2/23/2027

Additional CPE details can be found here.

Recent updates to U.S. guidelines for HIV post‑exposure prophylaxis (PEP) provide modernized recommendations for both non‑occupational and occupational exposures — reflecting advances in antiretroviral therapy and evolving evidence. This course summarizes key changes, including preferred regimens, testing/follow‑up modifications, and special‑population considerations, and explores how these updates influence clinical practice. You will gain the practical knowledge needed to inform prompt PEP decision‑making, patient counseling, and care coordination.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Kenric Ware, Pharm D
Clinical Associate Professor of Pharmacy Practice
Mercer University

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Identify current guideline recommendations for initiating HIV PEP after occupational and non-occupational exposure.
2. Describe key considerations for selecting and managing HIV PEP regimens.

Rachel Maynard and Kenric Ware have no relevant financial relationships with ineligible companies to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-052-H01-P
Initial release date: 2/16/2026
Expiration date: 2/16/2027
Additional CPE details can be found here.